The research landscape patients rarely see
Britain has one of the busiest clinical research networks in Europe, and diabetes sits at the heart of it. The NHS runs its Type 2 Diabetes Path to Remission Programme, while university teams from Belfast to Bristol test everything from weekly injections to digital coaching apps. For an ordinary patient the appeal is down to earth: taking part can mean closer monitoring, newer treatment options and a care team that actually looks at your numbers.
Yet most people never hear about these opportunities. The reasons are familiar. GP appointments are short, and diabetes clinics are often stretched. Information sits scattered across hospital websites, research registries and academic pages that were not written with patients in mind. And then there is the worry of signing up to something that sounds complicated. A common fear is becoming a test subject with no control over what happens next.
The reality is different. Every study in the UK runs under ethical review, and your consent can be withdrawn at any time. That principle is worth holding onto before we look at what is being tested right now.
New trials across the country in 2026
The list of recruiting studies keeps growing. At Ulster University, researchers are recruiting adults with prediabetes or type 2 diabetes and a BMI between 25 and 50 for a study on whether omega-3 supplements can slow the progression of the condition. In Bristol, the University of the West of England is testing a four-week digital programme built to reduce diabetes distress and support emotional wellbeing, open to adults with type 1 or type 2 diabetes anywhere in the UK. Oxford Brookes University is looking for people aged 40 to 65 with type 2 diabetes to explore whether beetroot juice improves cardiovascular responses after exercise.
There are larger, industry-backed studies too. Bradford Teaching Hospitals has launched two trials of a weekly injection designed to lower blood sugar and support weight loss, open to adults living with obesity or overweight, with or without type 2 diabetes. A phase 2 study sponsored by Eli Lilly is recruiting participants with type 2 diabetes who are already on a stable dose of semaglutide or tirzepatide, with sites in Birmingham, Blackpool, Bristol, Bromborough and Newcastle. Earlier this year, Diabetes UK also highlighted a pancreatic gene therapy candidate that aims to produce GLP-1 on demand after a single treatment, with first human trials planned during 2026.
| Study focus | Who can join | Where it runs | What participation involves | Notable detail |
|---|
| Omega-3 and type 2 progression | Adults with prediabetes or type 2, BMI 25-50 | Ulster University, in person | Supplement regimen plus regular blood checks | Runs through to late 2026 |
| Digital emotional wellbeing | Adults 18+ with type 1 or type 2 | Online, UK-wide | Four-week self-guided programme | Includes wellbeing questionnaires |
| Beetroot juice and exercise recovery | Adults 40-65 with type 2 | Oxford Brookes University | Two lab visits with light cycling | Blood sugar and blood pressure measured |
| Weekly injection for weight and glucose | Adults 18+ with obesity or overweight | Bradford Teaching Hospitals | Regular injections and reviews | Two trials testing different doses |
| Investigational add-on therapy | Type 2 on semaglutide or tirzepatide | Birmingham, Blackpool, Bristol, Bromborough, Newcastle | Oral or injected study treatment with follow-up | Phase 2, placebo-controlled |
| Pancreatic gene therapy | Planned cohort once approved | To be confirmed | Single endoscopic procedure in later stages | First human data expected in 2026 |
The pattern is worth noting. Some trials chase remission through weight loss, others test smart technology, and a growing number focus on the emotional side of living with the condition. Whatever your age or how long you have had diabetes, there is likely a study matching your situation.
A simple route into diabetes management trials UK
Finding the right trial does not require a medical degree. Start with the team you already trust: your GP or diabetes specialist nurse can tell you whether research is running at your local NHS trust and whether you might qualify. Then register with national platforms. The Diabetes UK clinical trials page lists live studies by region, and Research for the Future lets people with diabetes share their details with NHS research teams who will contact them when something relevant appears nearby. Northern Ireland residents can also check the Clinical Research Network directories for studies hosted by their health trusts.
Once you see a study that fits, the path is usually the same. You complete a short screening call to confirm eligibility. If you pass, the team walks you through the consent process, explains the schedule and makes clear you can step away at any point. Visits are planned around work and family life where possible, and the study team covers the cost of the investigational treatment, so you are not paying for the medicine under investigation. Ask about travel expenses when you speak to the site, as support varies.
What a study actually feels like
Margaret, a retired teacher from Leeds, joined a weight management study through her local NHS trust two years into her type 2 diagnosis. She had been managing on tablets but her HbA1c kept creeping up. The study involved a structured low-calorie meal plan with monthly reviews, and she lost just over 13 kilograms in the first year. Her blood sugar returned to a non-diabetic range, and she now takes less medication than before. She describes the trial as the most supported she has felt since her diagnosis.
Her experience fits the published evidence. Landmark research into primary care-led weight management in the UK found that nearly half of participants who completed the programme reached remission after one year, and a significant share lost 15 kilograms or more. Real-world results from the NHS Path to Remission Programme, reported in the Lancet family of journals, showed average weight loss of around 14 percent among those who completed the plan, with remission possible outside tightly controlled research settings.
Trials are not only about weight, though. The Address 2 study at Berkshire Healthcare is collecting information and optional blood samples from people recently diagnosed with type 1 diabetes and their siblings, to build a clearer picture of the condition. It is an observational study, which means no new medicine and no change to your care, yet it helps shape future treatment. For many participants, the quieter studies are just as valuable as the headline-grabbing ones.
Carry on the conversation
If you have diabetes, or care for someone who does, the simplest next step is a five-minute conversation with your usual care team. Ask what is running locally, then browse the Diabetes UK research pages over a cup of tea. You might find a study that suits you today, or you might simply learn what is coming down the line.
The questions you bring matter as much as the answers researchers seek. So bring your own: how much time will this take, what happens to my data, will my usual medication change. A good study team welcomes all of it. That is how diabetes management trials UK work best, as a partnership between people who live with the condition and the researchers who want to understand it better.
研究の知恵